

DT07 Rec'd PCT/PTO 11 FEB 2005


PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO TRANSMITTAL FORM FEB 11 2005 Please be used for correspondence after initial filing	Application Number	10/500,521	
	Filing Date	June 30, 2004	
	First Named Inventor	Gideon Schreiber	
	Art Unit	Not yet assigned	
	Examiner Name	Not yet assigned	
Total Number of Pages in This Submission	10	Attorney Docket Number	05558.0018.PCUS00

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return-receipt postcard.
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Howrey Simon Arnold & White, LLP		
Signature			
Printed name	Teddy C. Scott, Jr., Ph.D.		
Date	February 8, 2005	Reg. No.	53,573

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Teddy C. Scott, Jr., Ph.D.	Date	February 8, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Best Available Copy

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant(s): Gideon Schreiber
App. No.: 10/500,521
Conf. No.: 7709
Filing Date: June 30, 2004
Title: IFNAR2 MUTANTS, THEIR
PRODUCTION AND USE
Art Unit: Not yet assigned
Examiner: Not yet assigned

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date:

02/08/05

Date


Teddy C. Scott, Jr., Ph.D.
Registration No. 53,573

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 AND 1.98

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Forms PTO/SB/08A and PTO/SB/08B be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of a first Office Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b)(3).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed


necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey Simon Arnold & White, LLP Deposit Account 08-3038.

Respectfully submitted,

HOWREY SIMON ARNOLD & WHITE, LLP

Dated: February 8, 2005

By:



Teddy C. Scott, Jr., Ph.D.
Registration No.: 53,573
Customer No.: 22930

HOWREY SIMON ARNOLD & WHITE, LLP
321 N. Clark Street, Suite 3400
Chicago, IL 60661
(312) 595-1239 (main)
(312) 846-5621 (direct)
(312) 595-2250 (fax)

10 Rec'd FEB 11 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/500,521
Filing Date	June 30, 2004
First Named Inventor	Gideon Schreiber
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	05558.0018.PCUS00

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A4	Re 33,653	07-30-1991	Mark, et al.	
	A1	4,588,585	05-13-1986	Mark, et al.	
	A3	4,737,462	04-12-1988	Mark, et al.	
	A8	4,904,584	02-27-1990	Shaw	
	A2	4,959,314	09-25-1990	Mark, et al.	
	A6	4,965,195	10-23-1990	Namen, et al.	
	A7	5,017,691	05-21-1991	Lee, et al.	
	A5	5,116,943	05-26-1992	Koths, et al.	
	A9				
	A10				
	A11				
	A12				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	B1	EP 0220 574	05-06-1987	Yeda Research and Development Company, Limited		
	B2	EP 0679717 B1	08-25-1999	Yeda Research and Development Company, Limited		
	B3	EP1037658 B1	06/05/2002	Applied Research Sysetms ARS Holidng, N.V.		
	B4	WO 00/22146	04-20-2000	AMITAI		
	B5	WO 99/32141 A1	07/01/1999	Applied Research		

Examiner Signature	Date Considered
-------------------------------	----------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
DM_US8084656.v1

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/500,521
				Filing Date	June 30, 2004
				First Named Inventor	Gideon Schreiber
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	1	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C1	Alam, J., et al., "Comparative Pharmacokinetics and Pharmacodynamics of Two Recombinant Human Interferon Beta-1a (IFNβ-1a) Products Administered Intramuscularly in Healthy Male and Female Volunteers", Pharmaceutical Research, Vol. 14, No. 4 (1997)	
	C2	Alan, R., et al., "Interferon αβ Selectively Antagonises Down-Regulation of Mannosyl-Fucosyl Receptors on Activated Macrophages by Interferon γ," Biochem. Biophys. Res. Commun., 136(2); pps. 737-744 (April 1986)	
	C3	Anfinsen, C., "Principles that Govern the Folding of Protein Chains," Science, Vol. 181, No. 4096, July 20, 1973.	
	C4	Baron, S., et al., "The Interferons: Mechanisms of Action and Clinical Applications," JAMA, Vol. 266, No. 10, pp. 1375-1383, September 11, 1991	
	C5	Baron, S., et al., "The Interferons: a Biological System with Therapeutic Potential in Viral Infections," Antiviral Research, Vol. 24, pp. 97-110 (1994)	
	C6	Chill, J., et al., "The Human Interferon Receptor: NMR-Based Modeling, Mapping of the IFN-α2 Binding Site, and Observed Ligand-Induced Tightening," Biochemistry, Vol. 41, pp. 3575-3585 (2002)	
	C7	Christofinis, G., et al., "Interferon Production by Human Lymphoblastoid Cell Lines of Different Origins," J. Gen. Virol., Vol. 52, pp. 169-171 (1981)	
	C8	Colamonici, O., et al., "Identification of a Novel Subunit of the Type I Interferon Receptor Localized to Human Chromosome 21," The Journal of Biological Chemistry, Vol. 268, No. 15, pp. 10895-10899, May 25, 1993	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if known	
				Application Number	10/500,521
				Filing Date	June 30, 2004
				First Named Inventor	Gideon Schreiber
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	2	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T²
	C9	Colamonici, O., et al., "Multichain Structure of the IFN- α Receptor on Hematopoietic Cells," The Journal of Immunology, Vol. 148, No. 7, pp. 2126-2132, April 1, 1992	
	C10	Curtis, B., et al., "Enhanced Hematopoietic Activity of a Human Granulocyte/Macrophage Colony-Stimulating Factor-Interleukin 3 Fusion Protein," Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 5809-5813 (July 1991)	
	C11	Cusi, M., et al., "Harlequin Granulocyte-Colony Stimulating Factor Interleukin 6 Molecules with Bifunctional and Antagonistic Activities," Immunotechnology, Vol. 3, pp. 61-69 (1997)	
	C12	Domanski, P., et al., "Cloning and Expression of a Long Form of the β Subunit of the interferon $\alpha\beta$ Receptor That is Required for Signaling," The Journal of Biological Chemistry, Vol. 270, No. 37, pp. 21606-21611, September 15, 1995	
	C13	Dron et al., "Interferon $\alpha\beta$ Gene Structure and Regulation in Interferon: Principals and Medical Applications," Baron et al., Editors, University of Texas Medical Branch: Galveston, TX, pps. 33-45 (1992)	
	C14	Duncan, G., et al., "The Transcription Factor Interferon Regulatory Factor-1 Is Essential for Natural Killer Cell Function in Vivo," J. Exp. Med., Vol. 184, pp. 2043-2048 (November 1996)	
	C15	Edgington, S., "Biotech Products as Drug Leads", <u>Biotechnology</u> , Vol. 13, p. 649 (July 1995)	
	C16	Ezekowitz, R., et al., "Interferon α/β Selectively Antagonises Down-Regulation of Mannosyl-Fucosyl Receptors on Activated Macrophages by Interferon," Biochemical and Biophysical Research Communications, Vol. 136, No. 2, pp. 737-744, April 29, 1986	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/500,521
				Filing Date	June 30, 2004
				First Named Inventor	Gideon Schreiber
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	3	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C17	Fierlbeck, G., et al., "Pharmacodynamics of Recombinant IFN- β During Long-Term Treatment of Malignant Melanoma," Journal of Interferon and Cytokine Research, Vol. 16, pp. 777-781 (1996)	
	C18	Grantham R., Amino Acid Difference Formula to Help Explain Protein Evolution," Science, Vol. 185, pp. 862-864, September 6, 1974	
	C19	Ibanez, C., et al., "Chimeric Molecules With Multiple Neurotrophic Activities Reveal Structural Elements Determining the Specificities of NGF and BDNF", The EMBO Journal., Vol. 10, No. 8, pp. 2105-2110 (1991)	
	C20	Jacobs, L., et al., "Intrathecaly Administered Natural Human Fibroblast Interferon Reduces Exacerbations of Multiple Sclerosis," Arch Neurol., Vol. 44, pp. 589-595 (June 1987)	
	C21	Keown, W., et al., "Methods for Introducing DNA into Mammalian Cells," Methods in Enzymology, Vol. 185, pp. 527-537 (1990)	
	C22	Lengyel, P., "Biochemistry of Interferons and Their Actions," Ann. Rev. Biochem., Vol. 51, pp. 251-282, (1982)	
	C23	Lewerenz, M., et al., "Shared Receptor Components but Distinct Complexes for α and β Interferons," J. Mol. Biol., Vol. 282, pp. 585-599 (1998)	
	C24	Lutfalla, G., "Mutant USA Cells Are Complemented by an Interferon- $\alpha\beta$ Receptor Subunit Generated by Alternative Processing of a New Member of a Cytokine Receptor Gene Cluster", The EMBO Journal, Vol. 14, No. 20, pp. 5100-5108 (1995)	
	C25	Novick, D., et al., "Soluble Interferon- α Receptor Molecules are Present in Body Fluids," FEBS, Vol. 314, No. 3, pp. 445-448 (December 1992)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DM_US8084657.v1

10 Rec'd FEB 11 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/500,521
				Filing Date	June 30, 2004
				First Named Inventor	Gideon Schreiber
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	4	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C26	Novick, D., et al., "Soluble and Membrane-Anchored Forms of the Human IFN- α/β Receptor," Journal of Leukocyte Biology, Vol. 57, pp. 712-718 (May 1995)	
	C27	Novick, D., et al., "The Human Interferon α/β Receptor: Characterization and Molecular Cloning," Cell, Vol. 77, pp. 391-400, May 6, 1994	
	C28	Olins, P., et al., "Recent Advances in Heterologous Gene Expression In <i>Escherichia Coli</i> ", Current Opinion in Biotechnology, Vol. 4 (5), pp. 520-525 (1993)	
	C29	Pestka, S., et al., "Interferons and Their Actions," Ann. Rev. Biochem., Vol. 56, pp. 727-777 (1987)	
	C30	Piebler, J., et al., "Mutational and Structural Analysis of the Binding Interface between Type I Interferons and their Receptor Ifnar2," J. Mol. Biol., Vol. 294, No. 1, pp. 223-237 (1999)	
	C31	Piebler, J., "Fast Transient Cytokine-Receptor Interactions Monitored in Real Time by Reflectometric Interference Spectroscopy," Analytical Biochemistry, Vol. 289, pp. 173-186 (2001)	
	C32	Piebler, J., et al., "Biophysical Analysis of the Interaction of Human Ifnar2 Expressed in <i>E. coli</i> with IFN α 2," J. Mol. Biology, Vol. 289, pp. 57-67 (1999)	
	C33	Platanias L., et al., "Differences in Interferon α and β Signaling," The Journal of Biological Chemistry, Vol. 271, No. 39, pp. 23630-23633, September 27, 1996	
	C34	Platanias, L., et al., "Characterization of the α Subunit of the IFN- α Receptor," The Journal of Immunology, Vol., 150, No. 8, pp. 3382-3388, April 15, 1993	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO RECD 02/27/05

FEB 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/500,521
				Filing Date	June 30, 2004
				First Named Inventor	Gideon Schreiber
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	5	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C35	Platanias, L., et al., "Tyrosine Phosphorylation of the α and β Subunits of the Type 1 Interferon Receptor," J. Biol. Chem. 269 (27): pps. 17761-17764 (July 1994)	
	C36	Qureshi, S., et al., "Function of Stat2 Protein in Transcriptional Activation by Alpha Interferon," Molecular and Cellular Biology, Vol. 16, No. 1, pp. 288-293 (Jan. 1996)	
	C37	Reff, Mitchell, "High-Level Production of Recombinant Immunoglobulins in Mammalian Cells," Current Opinion in Biotechnology, Vol. 4, pp. 573-576 (1993)	
	C38	Reuveny S., et al., "Effect of Temperature and Oxygen on Cell Growth and Recombinant Protein Production in Insect Cell Cultures," Appl. Microbiol. Biotechnol., Vol. 38, pp. 619-623 (1993)	
	C39	Roisman, L., et al., "Structure of the Interferon-Receptor Complex Determined by Distance Constraints from Double-Mutant Cycles and Flexible Docking," PNAS, Vol. 98, No. 23, pp. 13231-13236, November 6, 2001	
	C40	Rubenstein, D., et al., "Advances in the Treatment of Virus Diseases," Practitioner, 207 (240): pps. 510-515 (October 1971)	
	C41	Salmon, P., et al., "Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon- β in Healthy Male Volunteers," Journal of Interferon and Cytokine Research, Vol. 16, pp. 759-764 (1996)	
	C42	Sharf, R., et al., "Functional Domain Analysis of Interferon Consensus Sequence Binding Protein (ICSBP) and Its Association with Interferon Regulatory Factors," The Journal of Biological Chemistry, Vol. 270, No. 22, pp. 13063-13069, June 2, 1995	
	C44	Smith, G., et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Molecular and Cellular Biology, Vol. 3, No. 12, pp. 2156-2165 (Dec. 1983)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DM_US8084657.v1

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/500,521
				Filing Date	June 30, 2004
				First Named Inventor	Gideon Schreiber
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	6	of	6	Attorney Docket Number	05558.0018.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C45	Tan, Y., et al., "The Linkage of Genes for the Human Interferon-Induced Antiviral Protein and Indophenol Oxidase-B Traits to Chromosome G-21," Journal of Experimental Medicine, Vol. 137, pp. 317-330 (1973)	
	C46	Terlizzese, M., et al., "In Vitro Comparison of Inhibiting Ability of Soluble TNF Receptor p75 (TBP II) vs. Soluble TNF Receptor p 55 (TBP I) Against TNF- α and TNF- β ," Journal of Interferon and Cytokine Research, Vol. 16, No. 12, pp. 1047-1053 (1996)	
	C47	Utsumi, J., et al., "Characterization of <i>E. coli</i> -Derived Recombinant Human Interferon- β as Compared with Fibroblast Human Interferon- β ," J. Biochem., Vol. 101, No. 5, pp. 1199-1208 (1987)	
	C48	Uze, G., et al., "Genetic Transfer of a Functional Human Interferon α Receptor into Mouse Cells: Cloning and Expression of Its cDNA," Cell, Vol. 60, pp. 225-234, January 26, 1990	
	C49	Weismann, et al., "Structure and Expression of Human Alpha-Interferon Genes," Princess Takamatsu Symp., Vol. 12, pps. 1-22 (1982)	
	C50	Yan, H., et al., "Molecular Characterization of an Alpha Interferon Receptor 1 Subunit (IFNaR1) Domain Required for TYK2 Binding and Signal Transduction," Molecular and Cellular Biology, Vol. 16, No. 5, pp. 2074-2082 (May 1996)	
	C51	Yang, C., et al., "Direct Association of STAT3 with IFNAR-1 Chain of the Human Type I Interferon Receptor," The Journal of Biological Chemistry, Vol. 271, No. 14., pp. 8057-8061, April 5, 1996	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.